


Amendments to the Claims:

Please amend the claims as follows:

Please delete claims 35 and 36 without prejudice or disclaimer to any patentable subject matter contained therein.

1. (Amended) A compound of formula I



its enantiomers, diastereomeric or tautomeric isomers, or a pharmaceutically acceptable salt wherein,

R¹ is

- (a) Cl
- (b) Br
- (c) F, or
- (d) CN;

R² is

- (a) C₁₋₄ alkyl optionally substituted by one or more OH or C₁₋₄ alkoxy, or
- (b) (CH₂)_mOCH₃CH₂OH;

R³ is C₁₋₂ alkyl;

R⁴ is phenyl optionally fused to a benzene or pyridine ring, and substituted with one or more R⁶;

R⁵ is

- (a) H, or
- (b) C₁₋₂ alkyl optionally substituted by OH;

R⁶ is

- (a) halo,
- (b) OCF₃,
- (c) cyano,
- (d) nitro,
- (e) CONR⁷R⁸,
- (f) NR⁷R⁸,
- (g) C₁₋₇ alkyl which is optionally partially unsaturated and optionally substituted by one or more R⁹,
- (h) O(CH₂CH₂O)_nR¹⁰,

- (j) CO_2R^{10} ,
- (k) phenyl optionally substituted by halo, C_{1-7} alkyl or C_{1-7} alkoxy,
- (m) imidazolyl,
- (n) $\text{S(O)}_m\text{NR}^7\text{R}^8$,
- (o) NHC(=O)R^{10} , or
- (p) any two adjacent R^6 substituents taken together constitute a group of the formula – $\text{O(CH}_2)_m\text{O-}$, $\text{-(NH)(CO)(CH}_2)_j\text{O-}$, or $\text{-(CH}_2)_i\text{-}$;

R^7 and R^8 are independently

- (a) H,
- (b) phenyl optionally substituted by halo, C_{1-7} alkyl or C_{1-7} alkoxy,
- (c) C_{1-7} alkyl which is optionally substituted by one or more OR^{10} , phenyl, or halo substituents
- (d) C_{3-8} cycloalkyl,
- (e) (C=O)R^{11} ,
- (f) R^7 and R^8 together with the nitrogen to which they attach form a het, wherein het is a five- (5), or six- (6) membered heterocycle ring having one (1), two (2), or three (3) heteroatoms selected from the group consisting of oxygen, sulfur or nitrogen, wherein het is optionally substituted with C_{1-4} alkyl;

R^9 is

- (a) oxo,
- (b) phenyl optionally substituted by halo, C_{1-7} alkyl or C_{1-7} alkoxy,
- (c) OR^{10} ,
- (d) $\text{O(CH}_2\text{CH}_2\text{)OR}^{10}$,
- (e) SR^{10} ,
- (f) NR^7R^8 ,
- (g) halo
- (h) CO_2R^{10} ,
- (i) $\text{CONR}^{10}\text{R}^{10}$, or
- (j) C_{3-8} cycloalkyl optionally substituted by OR^{10} ;

R^{10} is

- (a) H,
- (b) C_{1-7} alkyl
- (c) C_{3-8} cycloalkyl or
- (d) phenyl optionally substituted by halo, C_{1-7} alkyl or C_{1-7} alkoxy

R^{11} is

- (a) C_{1-7} alkyl
- (b) C_{3-8} cycloalkyl, or
- (c) Phenyl optionally substituted by halo, C_{1-7} alkyl or C_{1-7} alkoxy;

i is 3 or 4

j is 0 or 1

n is 1, 2, 3, 4, or 5 and

each m is independently 1 or 2.

34. (Amended) A method of treating atherosclerosis and restenosis, mediated by herpesviral infection, comprising administering to a mammal in need thereof a therapeutic amount of a compound of claims 1 or 2.

37. (Amended) A compound of claim 1 which is

- (3) N-(4-Chlorobenzyl)-7-(2,3-dihydroxypropyl)-2-((((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,
- (4) N-(4-chlorobenzyl)-2-((((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-7-(3-hydroxypropyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,
- (5) N-(4-Chlorobenzyl)-7-(2-hydroxyethyl)-2-((((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,
- (6) N-(4-Chlorobenzyl)-2-((((2S)-2-hydroxy-2-(3-methoxyphenyl)ethyl)(methyl)-amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,
- (8) N-(4-Chlorobenzyl)-2-((((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-4-oxo-7-propyl-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,
- (9) N-(4-Chlorobenzyl)-2-((((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-7-(2-methoxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,
- (10) N-(4-Chlorobenzyl)-2-((((2S)-2-hydroxy-2-(4-cyanophenyl)ethyl)(methyl)-amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,
- (11) N-(4-Chlorobenzyl)-2-((((2S)-2-hydroxy-2-(3-cyanophenyl)ethyl)(methyl)-amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,
- (12) N-(4-Chlorobenzyl)-2-((((2S)-2-(4-(dimethylamino)phenyl)-2-hydroxyethyl)(methyl)amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,

- (13) N-(4-Chlorobenzyl)-2-((((2S)-2-hydroxy-2-(4-(hydroxymethyl)phenyl)ethyl)-(methyl)amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,
- (14) N-(4-Chlorobenzyl)-2-((((2S)-2-hydroxy-2-(4-nitrophenyl)ethyl)-(methyl)amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide, or a pharmaceutically acceptable salt thereof.

Amendments to the Drawings:

none